BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 16885561)

  • 1. Lineage-specific hematopoietic growth factors.
    Ferretti G; Papaldo P; Cognetti F
    N Engl J Med; 2006 Aug; 355(5):526; author reply 527. PubMed ID: 16885561
    [No Abstract]   [Full Text] [Related]  

  • 2. Does the concurrent use of anthracycline and granulocyte colony-stimulating factor influence the risk of secondary leukaemia in breast cancer women?
    Di Cosimo S; Ferretti G; Papaldo P; Carlini P; Fabi A; Ruggeri EM; Alimonti A; Nardoni C; Cognetti F
    Ann Oncol; 2005 Jul; 16(7):1209-10. PubMed ID: 15857847
    [No Abstract]   [Full Text] [Related]  

  • 3. Can granulocyte-colony stimulating factor worsen anemia?
    Dang C; Hudis C
    J Clin Oncol; 2006 Jul; 24(19):2985-6. PubMed ID: 16769981
    [No Abstract]   [Full Text] [Related]  

  • 4. [Cancer of the breast in young women: should chemotherapy be intensified?].
    Piccart MJ
    Pathol Biol (Paris); 1992 Nov; 39(9):843-4. PubMed ID: 1371604
    [No Abstract]   [Full Text] [Related]  

  • 5. Does granulocyte colony-stimulating factor worsen anemia in early breast cancer patients treated with epirubicin and cyclophosphamide?
    Papaldo P; Ferretti G; Di Cosimo S; Giannarelli D; Marolla P; Lopez M; Cortesi E; Antimi M; Terzoli E; Carlini P; Vici P; Botti C; Di Lauro L; Naso G; Nisticò C; Mottolese M; Di Filippo F; Ruggeri EM; Ceribelli A; Cognetti F
    J Clin Oncol; 2006 Jul; 24(19):3048-55. PubMed ID: 16769988
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inflammatory breast cancer outcome with epirubicin-based induction and maintenance chemotherapy: ten-year results from the French Adjuvant Study Group GETIS 02 Trial.
    Veyret C; Levy C; Chollet P; Merrouche Y; Roche H; Kerbrat P; Fumoleau P; Fargeot P; Clavere P; Chevallier B
    Cancer; 2006 Dec; 107(11):2535-44. PubMed ID: 17054108
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Importance of dose intensity in chemotherapy--lessons from adjuvant chemotherapy for early breast cancer].
    Tamura K
    Rinsho Ketsueki; 2009 Apr; 50(4):276-81. PubMed ID: 19404020
    [No Abstract]   [Full Text] [Related]  

  • 8. Acute myeloid leukaemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy.
    Ferretti G; Papaldo P
    Breast Cancer Res Treat; 2008 May; 109(1):187-8. PubMed ID: 17616805
    [No Abstract]   [Full Text] [Related]  

  • 9. Chronic myeloid leukemia following cyclophosphamide-containing chemotherapy in a breast cancer patient.
    Porta C; Casagranda I; Semino G; Moroni M; Ratto C
    Haematologica; 1993; 78(1):56-7. PubMed ID: 8387943
    [No Abstract]   [Full Text] [Related]  

  • 10. The increase of the rate of hemopoietic recovery and clinical benefit of the erythropoietin (EPO) and granulocyte colony-stimulating factor (G-CSF) with peripheral blood progenitor cells (PBPC) after intensive cyclic chemotherapy in high-risk breast cancer patients.
    Filip S; Vanásek J; Bláha M; Mericka P; Vávrová J; Podzimek K
    Neoplasma; 1999; 46(3):166-72. PubMed ID: 10613592
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The impact of schedule on acute toxicity and dose-intensity of high-dose chemotherapy with epirubicin and cyclophosphamide plus colony stimulating factors in advanced breast cancer.
    De Placido S; Lauria R; Carlomagno C; Perrone F; De Laurentiis M; Gallo C; Martignetti A; Bellelli T; Limite G; Petrella G; Bianco AR
    Int J Oncol; 1999 Aug; 15(2):339-46. PubMed ID: 10402245
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy.
    Hershman D; Neugut AI; Jacobson JS; Wang J; Tsai WY; McBride R; Bennett CL; Grann VR
    J Natl Cancer Inst; 2007 Feb; 99(3):196-205. PubMed ID: 17284714
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mobilization of peripheral blood progenitor cells (PBPC) through a combination of chemotherapy and G-CSF in breast cancer patients and a possibility of unprocessed whole blood collection.
    Vanásek J; Filip S; Medková V; Bláha M; Mericka P; Volenec K
    Bone Marrow Transplant; 1998 Jan; 21(2):123-6. PubMed ID: 9489627
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acute hematologic feasibility of G-CSF supported dose-escalated FEC therapy as adjuvant treatment after breast cancer surgery.
    Ottosson S; Magnusson K; Hultborn R
    Anticancer Res; 1999; 19(5C):4429-34. PubMed ID: 10650787
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An unusual cause of a marked leukocytosis and an abnormal blood film.
    Hargreaves T; Varey M; Kataria U; Renton B
    Br J Hosp Med (Lond); 2015 Mar; 76(3):174-5. PubMed ID: 25761812
    [No Abstract]   [Full Text] [Related]  

  • 16. Secondary leukemia after autologous peripheral blood progenitor cell transplantation for breast cancer.
    Sica S; Salutari P; Ciarli M; Piccirillo N; Laurenti L; Menichella G; Leone G
    Leukemia; 1997 Nov; 11(11):1990-2. PubMed ID: 9369440
    [No Abstract]   [Full Text] [Related]  

  • 17. Secondary acute leukemia following mitoxantrone-based high-dose chemotherapy for primary breast cancer patients.
    Kröger N; Damon L; Zander AR; Wandt H; Derigs G; Ferrante P; Demirer T; Rosti G; ; ;
    Bone Marrow Transplant; 2003 Dec; 32(12):1153-7. PubMed ID: 14647269
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FEC versus sequential docetaxel followed by epirubicin/cyclophosphamide as adjuvant chemotherapy in women with axillary node-positive early breast cancer: a randomized study of the Hellenic Oncology Research Group (HORG).
    Polyzos A; Malamos N; Boukovinas I; Adamou A; Ziras N; Kalbakis K; Kakolyris S; Syrigos K; Papakotoulas P; Kouroussis C; Karvounis N; Vamvakas L; Christophyllakis C; Athanasiadis A; Varthalitis I; Georgoulias V; Mavroudis D
    Breast Cancer Res Treat; 2010 Jan; 119(1):95-104. PubMed ID: 19636702
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sequential interleukin-3 and granulocyte-colony stimulating factor prior to and following high-dose etoposide and cyclophosphamide: a phase I/II trial.
    Bernstein SH; Fay JP; Christiansen NP; Pinero L; Shah D; Stephan M; Herzig GP
    Clin Cancer Res; 1997 Sep; 3(9):1519-26. PubMed ID: 9815838
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of therapy-related acute myeloid leukemia occurring in elderly non-Hodgkin lymphoma patients with low-dose cytarabine, aclarubicin and granulocyte colony-stimulating factor.
    Tatetsu H; Matsuno F; Takatsu N; Miyake H; Hoshino K; Nosaka K; Horikawa K; Hata H; Mitsuya H; Asou N
    Leuk Res; 2009 Jan; 33(1):197-200. PubMed ID: 18472159
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.